RELATED CONTENT
NEWS
- US Capitol Capsule: Biopharma essentials could get paddled in ugly lame duck session
- US Capitol Capsule: Industry group vexed over FDA generics leadership void
- Bad-mouthing emerging biosimilars seen as switch in Big Pharma sabotage tactic
- US Capitol Capsule: Poor image, branding problems harm US FDA's ability to attract top scientists
COMMENT
Other Informa Comment
FEATURES
- How Dennis Gillings took a gamble and built a $3.7bn business
- From Tysabri to bapi and back to the drawing board: Dale Schenk speaks

